A randomized comparative trial of continued abacavir/lamivudine plus efavirenz or replacement with efavirenz/emtricitabine/tenofovir DF in hypercholesterolemic HIV-1 infected individuals (Q28543212)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	A randomized comparative trial of continued abacavir/lamivudine plus efavirenz or replacement with efavirenz/emtricitabine/tenofovir DF in hypercholesterolemic HIV-1 infected individuals	scientific article

Statements

scholarly article

0 references

A randomized comparative trial of continued abacavir/lamivudine plus efavirenz or replacement with efavirenz/emtricitabine/tenofovir DF in hypercholesterolemic HIV-1 infected individuals (English)

0 references

hypercholesterolemia

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

abacavir/lamivudine

1 reference

based on heuristic

inferred from title

object named as

Jane Anderson

5

0 references

2

object named as

Chloe Orkin

0 references

author name string

Graeme J Moyle

1

0 references

Martin Fisher

3

0 references

Jyoti Dhar

4

0 references

Edmund Wilkins

6

0 references

Jacqueline Ewan

7

0 references

Ramin Ebrahimi

8

0 references

Hui Wang

9

0 references

language of work or name

0 references

publication date

2015

0 references

0 references

10

0 references

e0116297

0 references

2

0 references

copyright license

Creative Commons Attribution 4.0 International

6 February 2015

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319732

19 March 2017

No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319732

29 September 2017

Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319732

29 September 2017

Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319732

29 September 2017

Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319732

29 September 2017

Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319732

29 September 2017

The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in cardiovascular disease: a comprehensive review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319732

29 September 2017

Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319732

29 September 2017

One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319732

29 September 2017

CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319732

29 September 2017

Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319732

29 September 2017

Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319732

29 September 2017

Durability and outcome of initial antiretroviral treatments received during 2000--2005 by patients in the Swiss HIV Cohort Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319732

29 September 2017

Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319732

29 September 2017

Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319732

29 September 2017

Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0116297

21 January 2018

Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0116297

21 January 2018

A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0116297

21 January 2018

A randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtricitabine in efavirenz-treated HIV-1-infected individuals.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0116297

21 January 2018

The effect of tenofovir disoproxil fumarate on whole-body insulin sensitivity, lipids and adipokines in healthy volunteers

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0116297

21 January 2018

Beliefs about antiretroviral therapy, treatment adherence and quality of life in a 48-week randomised study of continuation of zidovudine/lamivudine or switch to tenofovir DF/emtricitabine, each with efavirenz

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0116297

21 January 2018

Increased reporting of detectable plasma HIV-1 RNA levels at the critical threshold of 50 copies per milliliter with the Taqman assay in comparison to the Amplicor assay

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0116297

21 January 2018

Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0116297

21 January 2018

Better maintained adherence on switching from twice-daily to once-daily therapy for HIV: a 24-week randomized trial of treatment simplification using stavudine prolonged-release capsules

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0116297

21 January 2018

Switching from twice-daily abacavir and lamivudine to the once-daily fixed-dose combination tablet of abacavir and lamivudine improves patient adherence and satisfaction with therapy

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0116297

21 January 2018

Identifiers

10.1371/JOURNAL.PONE.0116297

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

2015PLoSO..1016297M

0 references

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28543212&oldid=1858490335"